SCHEMBL219876

SCHEMBL219876

O=C(O)COCCN1CCN(Cc2ccccc2-c2ccc(Cl)cc2)CC1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 4/20 0.59
HRH2 P25021 2/20 0.59
HTR2A P28223 2/20 0.59
DRD3 P35462 2/20 0.59
HTR2B P41595 2/20 0.59
KCNH2 Q12809 2/20 0.59
USP2 O75604 2/20 0.59
SLC6A2 P23975 1/20 0.59
SLC6A4 P31645 1/20 0.59
SLC6A3 Q01959 1/20 0.59
TEK Q02763 1/20 0.59
TDP1 Q9NUW8 1/20 0.59
HTR7 P34969 4/20 0.51
HRH3 Q9Y5N1 1/20 0.49
BCL2 P10415 5/20 0.48
BAK1 Q16611 2/20 0.48
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
BCHE P06276 1/20 0.45
ACHE P22303 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5686168 0.99 HRH1 (0.60) HRH1HRH2HTR2ADRD3HTR2B
Hydrochloric Acid SCHEMBL219199 0.99 HRH1 (0.60) HRH1HRH2HTR2ADRD3HTR2B
SCHEMBL2058761 0.98 HRH1 (0.57) HRH1HRH2HTR2ADRD3HTR2B
Hydrochloric Acid SCHEMBL10930701 0.97 HRH1 (0.58) HRH1HRH2HTR2ADRD3HTR2B
SCHEMBL1569359 0.90 HTR7 (0.50) HRH1HRH2HTR2ADRD3HTR2B
Potassium Ion SCHEMBL2058535 0.89 HTR7 (0.49) HRH1HRH2HTR2ADRD3HTR2B
SCHEMBL2058741 0.89 HRH3 (0.49) HRH1HRH2HTR2ADRD3HTR2B
SCHEMBL5182319 0.88 HTR7 (0.53) HRH1HRH2HTR2ADRD3HTR2B
SCHEMBL7628259 0.88 HTR7 (0.48) HRH1HRH2HTR2ADRD3HTR2B
Water SCHEMBL10930920 0.88 HRH3 (0.48) HRH1HRH2HTR2ADRD3HTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8350031-B2 Processes for the synthesis of levocetirizine and intermediates for use therein CIPLA LIMITED (IN) 2013-01-08 US claimed
EP-1734918-B1 PHARMACEUTICAL COMPOSITION FOR TREATING HAIR LOSS AND BENIGN PROSTATIC HYPERPLASIA LEE EUN-JOO (KR) 2012-08-01 EP claimed
US-8088775-B2 Pharmaceutical composition for treating hair loss KIM, SOLOMON L. 2012-01-03 US claimed
US-20110184174-A1 Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein CIPLA LIMITED (IN) 2011-07-28 US claimed
US-7968549-B2 Diarylmethylpiperazines as therapeutic agents for viral myocarditis MATSUMORI AKIRA 2011-06-28 US claimed
EP-2307392-A2 PROCESSES FOR THE SYNTHESIS OF LEVOCETIRIZINE AND INTERMEDIATES FOR USE THEREIN Cipla Limited (IN) 2011-04-13 EP claimed
US-20100222364-A1 PHARMACEUTICAL COMPOSITION FOR TREATING HAIR LOSS AND BENIGN PROSTATIC HYPERPLASIA KIM, SOLOMON L. 2010-09-02 US claimed
WO-2009147389-A2 PROCESSES FOR THE SYNTHESIS OF LEVOCETIRIZINE AND INTERMEDIATES FOR USE THEREIN CIPLA LIMITED (IN) 2009-12-10 WO claimed
US-20080287459-A1 Pharmaceutical Composition for Treating Hair Loss and Benign Prostatic Hyperplasia LEE EUN-JOO 2008-11-20 US claimed
US-20070142400-A1 For treatment of allergies; antihistamines COSSEMENT ERIC 2007-06-21 US claimed
US-20030105113-A1 Enantiomers of 1-[ (4-chlorophenyl) phenylmethyl ] -4-[ (4-methylphenyl) sulfonyl ] piperazine COSSEMENT ERIC (BE) 2003-06-05 US claimed
US-6469009-B1 MIXTURE CONSISTING ESSENTIALLY OF PSEUDOEPHEDRINE AND COMPOUND SELECTED FROM 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)-ACETIC ACID OR AMIDE DERIVATIVES, THEIR INDIVIDUAL OPTICAL ISOMERS OR PHARMACEUTICALLY ACCEPTABLE SALTS UCB, S.A. (BE) 2002-10-22 US claimed
US-6413970-B1 Pharmaceutical composition for treating viral diseases UCB S.A. (BE) 2002-07-02 US claimed
EP-0927173-B1 SUBSTITUTED [2-(1-PIPERAZINYL)ETHOXY]METHYL UCB SA (BE) 2002-06-12 EP claimed
US-20010020023-A1 Pharmaceutical compositions for the treatment of rhinitis UCB PHARMA, S.A. (BE) 2001-09-06 US claimed
US-6255487-B1 PREPARING 2-(2-(4-((4-CHLOROPHENYL)PHENYLMETHYL)-1-PIPER-AZINYL)ETHOXY)ACETIC ACID VIA REACTING SUBSTITUTED (2-((1-PIPERAZINYL)ETHOXY)METHYL COMPOUND WITH A DIPHENYLMETHYL HALIDE, THEN HYDROLYZING IN ALCOHOLIC MEDIUM WITH ACID/BASE UCB, S.A. (BE) 2001-07-03 US claimed
EP-0955295-A1 Therapeutically active levorotatory and dextrorotatory 1-((4-chlorophenyl)phenylmethyl) piperazines UCB, S.A. (BE) 1999-11-10 EP claimed
EP-0617028-A1 Enantiomers of 1-(4-chlorophenyl)phenylmethyl)-4-(4-methylphenyl)sulfonyl piperazine U C B, S.A. (BE) 1994-09-28 EP claimed
US-4525358-A ANTIHISTAMINES, ANTIALLERGENS, ANTISPASMODICS, BRONCHODILATORS UCB PHARMACEUTICALS, INC. (US) 1985-06-25 US claimed
EP-0058146-B1 2-(4-(DIPHENYLMETHYL)-1-PIPERAZINYL)-ACETIC ACIDS AND THEIR AMIDES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS U C B, S.A. (BE) 1984-06-27 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110184174-A1 Processes for the Synthesis of Levocetirizine and Intermediates for Use Therein CYP3A5, CYP4A11, IL5 HRH1 82/4885HRH2 148/4885HTR2A 382/4885
US-20030105113-A1 Enantiomers of 1-[ (4-chlorophenyl) phenylmethyl ] -4-[ (4-methylphenyl) sulfonyl ] piperazine RPLP1, QDPR, PRLHR HRH1 135/4885HRH2 224/4885HTR2A 30/4885
US-20070142400-A1 For treatment of allergies; antihistamines HRH2, HRH1, HRH4 HRH1 2/4885HRH2 1/4885HTR2A 140/4885
US-20080287459-A1 Pharmaceutical Composition for Treating Hair Loss and Benign Prostatic Hyperplasia SHBG, CYP17A1, NR5A1 HRH1 3049/4885HRH2 3256/4885HTR2A 1417/4885
US-20010020023-A1 Pharmaceutical compositions for the treatment of rhinitis HRH4, HRH2, HRH1 HRH1 3/4885HRH2 2/4885HTR2A 180/4885
US-20100222364-A1 PHARMACEUTICAL COMPOSITION FOR TREATING HAIR LOSS AND BENIGN PROSTATIC HYPERPLASIA BPHL, ACP3, PSAP HRH1 2676/4885HRH2 3228/4885HTR2A 2102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.